×
About 14,517 results

ALLMedicine™ Hypertrophic Cardiomyopathy Center

Research & Reviews  7,033 results

When is an obscurin variant pathogenic? The impact of Arg4344Gln and Arg4444Trp variant...
https://doi.org/10.1093/hmg/ddab010
Human Molecular Genetics; Fukuzawa A, Koch D et. al.

Jan 13th, 2021 - Obscurin is a giant muscle protein that connects the sarcomere with the sarcoplasmic reticulum, with poorly understood structural and signalling functions. Increasingly, obscurin variants are implicated in the pathophysiology of cardiovascular dis...

Thromboembolism in Patients with Hypertrophic Cardiomyopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797548
International Journal of Medical Sciences; Liu L, Liu Z et. al.

Jan 13th, 2021 - Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embo...

QRS-T angle in patients with Hypertrophic Cardiomyopathy - A comparison with Cardiac Ma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797532
International Journal of Medical Sciences; Jensen CJ, Lambers M et. al.

Jan 13th, 2021 - Objective: We sought to investigate the possible association of a wide QRS-T angle on the surface EKG and myocardial fibrosis on contrast-enhanced cardiovascular magnetic (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM). Background...

Association Between Three-Dimensional Left Ventricular Outflow Tract Area and Gradients...
https://doi.org/10.1053/j.jvca.2020.12.014
Journal of Cardiothoracic and Vascular Anesthesia; Moreno Garijo J, Amador Y et. al.

Jan 12th, 2021 - Determine whether the intraoperative three-dimensional left ventricular outflow tract cross-sectional area may be inversely correlated with pressure gradients as a determinant of surgical success after septal myectomy in hypertrophic cardiomyopath...

Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.
https://doi.org/10.1161/CIRCHEARTFAILURE.120.008006
Circulation. Heart Failure; Margulies KB, Prosser BL

Jan 12th, 2021 - Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.|2021|Margulies KB,Prosser BL,|

see more →

Guidelines  15 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JC...
https://doi.org/10.1253/circj.CJ-66-0122
Circulation Journal : Official Journal of the Japanese Circulation Society;

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Tas...
https://doi.org/10.1093/eurheartj/ehu284
European Heart Journal; , Elliott PM et. al.

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:...
https://doi.org/10.1016/j.jtcvs.2011.10.019
The Journal of Thoracic and Cardiovascular Surgery; , et. al.

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:...
https://doi.org/10.1016/j.jacc.2011.06.011
Journal of the American College of Cardiology; Gersh BJ, Maron BJ et. al.

Nov 14th, 2011 - 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ame...

see more →

Clinicaltrials.gov  7,227 results

When is an obscurin variant pathogenic? The impact of Arg4344Gln and Arg4444Trp variant...
https://doi.org/10.1093/hmg/ddab010
Human Molecular Genetics; Fukuzawa A, Koch D et. al.

Jan 13th, 2021 - Obscurin is a giant muscle protein that connects the sarcomere with the sarcoplasmic reticulum, with poorly understood structural and signalling functions. Increasingly, obscurin variants are implicated in the pathophysiology of cardiovascular dis...

Thromboembolism in Patients with Hypertrophic Cardiomyopathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797548
International Journal of Medical Sciences; Liu L, Liu Z et. al.

Jan 13th, 2021 - Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease, which has a marked heterogeneity in clinical expression, natural history, and prognosis. HCM is associated with a high prevalence of thromboembolic events (stroke and systemic embo...

QRS-T angle in patients with Hypertrophic Cardiomyopathy - A comparison with Cardiac Ma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797532
International Journal of Medical Sciences; Jensen CJ, Lambers M et. al.

Jan 13th, 2021 - Objective: We sought to investigate the possible association of a wide QRS-T angle on the surface EKG and myocardial fibrosis on contrast-enhanced cardiovascular magnetic (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM). Background...

Association Between Three-Dimensional Left Ventricular Outflow Tract Area and Gradients...
https://doi.org/10.1053/j.jvca.2020.12.014
Journal of Cardiothoracic and Vascular Anesthesia; Moreno Garijo J, Amador Y et. al.

Jan 12th, 2021 - Determine whether the intraoperative three-dimensional left ventricular outflow tract cross-sectional area may be inversely correlated with pressure gradients as a determinant of surgical success after septal myectomy in hypertrophic cardiomyopath...

Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.
https://doi.org/10.1161/CIRCHEARTFAILURE.120.008006
Circulation. Heart Failure; Margulies KB, Prosser BL

Jan 12th, 2021 - Tubulin Detyrosination: An Emerging Therapeutic Target in Hypertrophic Cardiomyopathy.|2021|Margulies KB,Prosser BL,|

see more →

News  205 results

New HCM Guidelines Make Shared Decision-making Top Priority
https://www.medscape.com/viewarticle/941365

Nov 19th, 2020 - Greater involvement of the patient and family in decision-making, clarity on the role of genetic testing and parameters for team-oriented care, and use of high-volume specialty centers are cornerstones of the first update in almost a decade of the...

Surgery Still Best Option in Obstructive HCM Despite EXPLORER-HCM Results
https://www.staging.medscape.com/viewarticle/939029

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

Surgery Still Best Option in Obstructive HCM Despite EXPLORER-HCM Results
https://www.medscape.com/viewarticle/939029

Oct 14th, 2020 - Among the landmark presentations at the recent European Society of Cardiology virtual congress was the presentation on the EXPLORER-HCM randomized controlled trial. In this study, simultaneously published in The Lancet, the investigational drug ma...

EXPLORER Trial Hints at Potential New Drug Option in Obstructive Hypertrophic Cardiomyopathy
https://www.staging.medscape.com/viewarticle/936542

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...

EXPLORER Trial Hints at Potential New Drug Option in Obstructive Hypertrophic Cardiomyopathy
https://www.medscape.com/viewarticle/936542

Aug 28th, 2020 - An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with the genetic disorder, suggests a placebo-controlled phas...

see more →

Patient Education  37 results see all →